Orthofix Medical Inc. revised earnings guidance for the year ending December 31, 2023. For the period, the company revised net sales to be in the range of $739 million to $744 million from previous guidance range of $752 million to $758 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.16 USD | +0.33% | +3.07% | +11.94% |
May. 09 | Orthofix Medical Inc. Announces FDA 510(K) Clearance for the Rodeo Telescopic Nail | CI |
May. 08 | Roth MKM Upgrades Orthofix Medical to Buy From Neutral With $20 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.94% | 567M | |
-5.46% | 182B | |
+3.31% | 114B | |
-3.45% | 68.38B | |
+6.23% | 52.46B | |
+8.03% | 44.25B | |
+7.52% | 43.55B | |
+25.19% | 32.69B | |
+17.85% | 26.73B | |
-0.38% | 25.79B |
- Stock Market
- Equities
- OFIX Stock
- News Orthofix Medical Inc.
- Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023